- Trials with a EudraCT protocol (285)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
285 result(s) found for: Columbia Suicide Severity Rating Scale.
Displaying page 1 of 15.
EudraCT Number: 2017-001599-46 | Sponsor Protocol Number: F1J-MC-HMGI | Start Date*: 2017-05-09 |
Sponsor Name:Eli Lilly and Company Limited | ||
Full Title: A Double-Blind, Efficacy and Safety Study of Duloxetine Versus Placebo in the Treatment of Children and Adolescents With Generalized Anxiety Disorder | ||
Medical condition: Generalized Anxiety Disorder | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2019-001518-40 | Sponsor Protocol Number: 848040001 | Start Date*: 2020-01-31 |
Sponsor Name:VU Medical Center | ||
Full Title: Netherlands study of Optimal, PERsonalized Antidepressant use (OPERA-DISCONTINUATION) | ||
Medical condition: Depression | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2018-004899-35 | Sponsor Protocol Number: 331-201-00191 | Start Date*: 2024-06-13 |
Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc. | ||
Full Title: A Phase 3, Multicenter, Open Label Trial to Evaluate the Long-term Safety and Tolerability of Brexpiprazole in Treatment of Children and Adolescents With Irritability Associated With Autism Spectru... | ||
Medical condition: Irritability Associated With Autism Spectrum Disorder | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2008-004443-11 | Sponsor Protocol Number: A5361022 | Start Date*: 2009-02-04 | |||||||||||
Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017 | |||||||||||||
Full Title: A 52-WEEK OPEN-LABEL SAFETY STUDY OF PD 0332334 IN SUBJECTS WITH GENERALIZED ANXIETY DISORDER | |||||||||||||
Medical condition: Generalized Anxiety Disorder | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-000064-28 | Sponsor Protocol Number: RAP-MD-33 | Start Date*: 2018-11-28 | |||||||||||
Sponsor Name:Allergan Ltd. | |||||||||||||
Full Title: A Randomized, Double-blind, Placebo-controlled, Multicenter Study of Rapastinel in the Prevention of Relapse in Patients with Major Depressive Disorder | |||||||||||||
Medical condition: Major depressive disorder | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Prematurely Ended) SE (Prematurely Ended) SK (Prematurely Ended) PL (Prematurely Ended) BG (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-002067-14 | Sponsor Protocol Number: 3151A6-2001 | Start Date*: 2015-04-03 |
Sponsor Name:Wyeth Research | ||
Full Title: 6-Month, Multicenter, Open-Label, Flexible-Dose Study To Evaluate Safety, Efficacy, And Tolerability Of Desvenlafaxine Succinate Sustained-Release Tablets In The Treatment Of Child And Adolescent O... | ||
Medical condition: Major Depressive Disorder | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2019-000282-20 | Sponsor Protocol Number: EBS-101-OL-001 | Start Date*: Information not available in EudraCT |
Sponsor Name:Emalex Biosciences, Inc. | ||
Full Title: A Multicenter, Open-Label, Extension Study Intended to Evaluate the Long-term Safety of Ecopipam Tablets in Children and Adolescent Subjects with Tourette’s Syndrome | ||
Medical condition: Children and Adolescent Subjects with Tourette’s Syndrome greater than or equal to 6 and less than or equal to 18 years of age | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: FR (Ongoing) PL (Completed) | ||
Trial results: View results |
EudraCT Number: 2017-000685-29 | Sponsor Protocol Number: B4Z-KL-LYEC | Start Date*: 2021-08-05 | |||||||||||
Sponsor Name:Eli Lilly and Company | |||||||||||||
Full Title: A Phase 3b, Randomized, Open-Label Assessment of Response to Various Doses of Atomoxetine Hydrochloride in Korean Pediatric Outpatients With Attention-Deficit/Hyperactivity Disorder | |||||||||||||
Medical condition: Attention-Deficit/Hyperactivity Disorder (ADHD) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-002425-30 | Sponsor Protocol Number: 0171 | Start Date*: 2020-03-17 |
Sponsor Name:Theravance Biopharma Ireland Limited | ||
Full Title: A Phase 3, 182-week, Open-Label, Extension Study to Investigate the Safety and Tolerability Study of TD-9855 in Treating Symptomatic Neurogenic Orthostatic Hypotension (symptomatic nOH) in Subjects... | ||
Medical condition: Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) DK (Completed) ES (Prematurely Ended) PL (Completed) EE (Completed) FR (Completed) PT (Prematurely Ended) AT (Prematurely Ended) BG (Prematurely Ended) DE (Prematurely Ended) HU (Completed) IT (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2013-000970-31 | Sponsor Protocol Number: TUD-ASLith-057 | Start Date*: 2013-11-27 | |||||||||||
Sponsor Name:Technische Universität Dresden | |||||||||||||
Full Title: Randomized, placebo-controlled multicenter trial of lithium plus treatment as usual (TAU) for acute suicidal ideation and behaviour in patients with suicidal major depressive episode | |||||||||||||
Medical condition: Diagnosis of a major depressive episode; inpatient at screening visit; suicidal ideation/behaviour present defined by a clinical rating of ≥ 8 on the Sheehan Suicidality Tracking Scale (S-STS) at... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-000243-27 | Sponsor Protocol Number: BUPROPION2019 | Start Date*: 2019-03-18 | |||||||||||
Sponsor Name:Odense University Hospital | |||||||||||||
Full Title: The effect of bupropion in peripheral neuropathic pain. A randomized, double-blind, placebo-controlled study. | |||||||||||||
Medical condition: Peripheral neuropathic , i.e. painful polyneuropathy, postherpetic neuralgia and pain after nerve injury (traumatic or surgical). | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-000211-16 | Sponsor Protocol Number: F1J-MC-HMFN | Start Date*: 2017-03-02 | |||||||||||
Sponsor Name:Eli Lilly and Company Limited | |||||||||||||
Full Title: F1J-MC-HMFN (a) An Open-Label Study of Tolerability, Safety, and Pharmacokinetics of Duloxetine in the Treatment of Children and Adolescents With Major Depressive Disorder | |||||||||||||
Medical condition: Major Depressive Disorder | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-004378-27 | Sponsor Protocol Number: CAFQ056A2299 | Start Date*: 2012-03-30 | |||||||||||
Sponsor Name:Novartis Farmacéutica, S.A. | |||||||||||||
Full Title: An open-label treatment study to evaluate the safety, tolerability and efficacy of AFQ056 in Parkinson?s patients with L-dopa induced dyskinesias | |||||||||||||
Medical condition: L-dopa induced dyskinesias in patients with Parkinson?s disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) HU (Completed) DE (Prematurely Ended) IT (Prematurely Ended) SK (Completed) AT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-000203-16 | Sponsor Protocol Number: SOMCT02 | Start Date*: 2018-06-18 | |||||||||||
Sponsor Name:SOM Biotech | |||||||||||||
Full Title: Phase IIa, double-blind, randomized, placebo-controlled study of the efficacy and safety of SOM3335 in Huntington`s disease (HD) patients with chorea movements. | |||||||||||||
Medical condition: Chorea movements associated with Huntington's Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-022744-21 | Sponsor Protocol Number: AB08003 | Start Date*: 2013-06-05 | ||||||||||||||||
Sponsor Name:AB Science | ||||||||||||||||||
Full Title: A 12-week, proof of concept prospective, randomized, double blind, phase 2a study to compare safety and efficacy of masitinib to placebo in the treatment of mood disorders in patients with antidepr... | ||||||||||||||||||
Medical condition: mood disorders associated to major depression or dysthymic disorder | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2011-003615-28 | Sponsor Protocol Number: SPD489-209 | Start Date*: 2012-12-21 |
Sponsor Name:Shire Development LLC | ||
Full Title: A Phase 2, Multicenter, Double-blind, Parallel-group, Randomized, Placebo-controlled, Forced-dose Titration, Dose-ranging Efficacy and Safety Study of SPD489 in Combination with an Antidepressant... | ||
Medical condition: Major Depressive Disorder | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2022-000271-39 | Sponsor Protocol Number: 2022-01 | Start Date*: 2022-09-02 | |||||||||||
Sponsor Name:Adeptio Pharmaceuticals Ltd | |||||||||||||
Full Title: Single-arm, open-label dose titration phase 2 clinical trial of (+)-α-DHTBZ for the treatment of tardive dyskinesia (TD) | |||||||||||||
Medical condition: Tardive dyskinesia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-003034-27 | Sponsor Protocol Number: BN29552 | Start Date*: 2016-07-13 | |||||||||||
Sponsor Name:Roche Farma, S.A en nombre de F. Hoffman-La Roche Ltd. | |||||||||||||
Full Title: A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE- BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, EFFICACY AND SAFETY STUDY OF CRENEZUMAB IN PATIENTS WITH PRODOMAL-TO-MILD ALZHEIMER?S DISEASE | |||||||||||||
Medical condition: Alzheimer?s Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) SE (Prematurely Ended) GB (Prematurely Ended) LT (Prematurely Ended) HU (Completed) PT (Prematurely Ended) CZ (Completed) FI (Prematurely Ended) BE (Prematurely Ended) DK (Completed) AT (Prematurely Ended) SI (Prematurely Ended) PL (Prematurely Ended) DE (Prematurely Ended) BG (Completed) HR (Completed) FR (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-004420-30 | Sponsor Protocol Number: CL3-95008-002 | Start Date*: 2018-10-04 | |||||||||||
Sponsor Name:Institut de Recherches Internationales Servier | |||||||||||||
Full Title: Efficacy and safety of bumetanide oral liquid formulation in children aged from 2 to less than 7 years old with Autism Spectrum Disorder. A 6-month randomised, double-blind, placebo controlled mult... | |||||||||||||
Medical condition: Autism Spectrum Disorder (ASD) | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) FR (Completed) ES (Prematurely Ended) NL (Not Authorised) HU (Completed) PT (Completed) PL (Prematurely Ended) IE (Prematurely Ended) CZ (Completed) SK (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-004327-13 | Sponsor Protocol Number: H8Y-MC-HBBV | Start Date*: 2012-02-06 | |||||||||||
Sponsor Name:Eli Lilly and Company | |||||||||||||
Full Title: Long-Term Open-Label Safety Study of Pomaglumetad Methionil in Patients with Schizophrenia | |||||||||||||
Medical condition: Schizophrenia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GR (Prematurely Ended) DE (Completed) ES (Prematurely Ended) BE (Prematurely Ended) AT (Prematurely Ended) SE (Prematurely Ended) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
